Cyclobenzaprine hydrochloride - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for cyclobenzaprine hydrochloride and what is the scope of patent protection?

Cyclobenzaprine hydrochloride is the generic ingredient in three branded drugs marketed by Teva Pharms Intl, Apotex, Macleods Pharms Ltd, Novast Labs, Twi Pharms Inc, Actavis Labs Fl Inc, Aiping Pharm Inc, Anda Repository, Aurobindo Pharma, Chartwell Rx, Graviti Pharms, Invagen Pharms, Jubilant Cadista, Kvk Tech, Oxford Pharms, Pliva, Prinston Inc, Rising, Rubicon, Sandoz, Sun Pharm Inds Ltd, Unichem, Watson Labs, and Janssen Res And Dev, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for cyclobenzaprine hydrochloride. Fifty-eight suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for cyclobenzaprine hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	24
NDAs:	25
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	58
Raw Ingredient (Bulk) Api Vendors:	110
Clinical Trials:	40
Patent Applications:	1,953
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cyclobenzaprine hydrochloride
What excipients (inactive ingredients) are in cyclobenzaprine hydrochloride?	cyclobenzaprine hydrochloride excipients list
DailyMed Link:	cyclobenzaprine hydrochloride at DailyMed

Recent Clinical Trials for cyclobenzaprine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Madigan Army Medical Center	Phase 4
Apsen Farmaceutica S.A.	Phase 3
Centre hospitalier de l'Université de Montréal (CHUM)	Phase 4

See all cyclobenzaprine hydrochloride clinical trials

Generic filers with tentative approvals for CYCLOBENZAPRINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	30MG	CAPSULE, EXTENDED RELEASE; ORAL
⤷ Sign Up	⤷ Sign Up	15MG	CAPSULE, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for cyclobenzaprine hydrochloride

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

Anatomical Therapeutic Chemical (ATC) Classes for cyclobenzaprine hydrochloride

M03BX	Other centrally acting agents
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for CYCLOBENZAPRINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMRIX	Extended-release Capsule	cyclobenzaprine hydrochloride	15 mg and 30 mg	021777	1	2008-08-11

US Patents and Regulatory Information for cyclobenzaprine hydrochloride

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Oxford Pharms	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	077209-002	Feb 3, 2006	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Actavis Labs Fl Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	071611-001	May 3, 1989	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Graviti Pharms	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	218936-001	Sep 12, 2024	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Rising	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	073144-001	May 30, 1991		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Actavis Labs Fl Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	071611-003	Feb 3, 2006	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Aiping Pharm Inc	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	072854-001	Nov 19, 1991		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Unichem	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	TABLET;ORAL	213324-001	Jul 6, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for cyclobenzaprine hydrochloride

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.